Synaptic Failure In Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Synaptic failure is a critical early event in neurodegenerative diseases, preceding neuronal loss and cognitive decline. Understanding the mechanisms of synaptic dysfunction is essential for developing therapies targeting synaptic protection and restoration.
Synapses are the fundamental units of neuronal communication, and their dysfunction is a hallmark of neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), and frontotemporal dementia (FTD). Synaptic failure occurs early in disease progression and correlates strongly with cognitive impairment, making it a key therapeutic target.
flowchart TD
A[Amyloid-Beta Oligomers] --> F[Synaptic Toxicity] -->
B[Alpha-Synuclein Aggregates] --> F
C[Tau Pathology) --> F
D[Oxidative Stress] --> F
E[Calcium Dysregulation] --> F
F --> G[Presynaptic Dysfunction] -->
G --> G1[Synaptophysin Loss] -->
G --> G2[Synapsin Dysfunction] -->
G --> G3[vesicle Depletion] -->
F --> H[Postsynaptic Dysfunction] -->
H --> H1[PSD-95 Degradation] -->
H --> H2[AMPA Receptor Internalization] -->
H --> H3[NMDA Receptor Dysregulation] -->
G --> I[Neurotransmitter Failure] -->
I --> I1[Glutamate Excitotoxicity)
I --> I2[Dopamine Depletion] -->
I --> I3[Cholinergic Decline] -->
H --> J[Spine Morphology Changes] -->
J --> J1[Spine Loss] -->
J --> J2[Spine Head Shrinkage] -->
J --> J3[Filopodia Extension] -->
I --> K[LTP Impairment] -->
J --> K
K --> L[Memory Formation Deficit] -->
I --> M[Synaptic Signaling Disruption] -->
M --> M1[CaMKII Dysfunction] -->
M --> M2[PKA Pathway Impairment] -->
M --> M3[ERK/MAPK Inhibition] -->
L --> N[Cognitive Decline] -->
N --> O[Clinical Dementia]
| Protein |
Function |
Changes in Neurodegeneration |
| Synaptophysin |
Major SV membrane protein |
Reduced expression |
| Synapsin I |
Vesicle tethering |
Phosphorylation dysregulation |
| Synaptotagmin |
Ca²⁺-triggered fusion |
Impaired vesicle release |
| VAMP2 |
SNARE complex |
Reduced neurotransmission |
- Quantal content reduction: Fewer vesicles per release site
- Release probability changes: Impaired Ca²⁺ sensitivity
- Vesicle cycling disruption: Endocytosis defects
- Synaptic vesicle depletion: Reduced vesicle pools
AMPA Receptors:
- GluA1/GluA2 subunit changes
- Internalization and degradation
- Reduced synaptic insertion
- Channel conductance alterations
NMDA Receptors:
- Excitotoxicity from overactivation
- Subunit composition changes (GluN2A→GluN2B)
- Synaptic vs extrasynaptic signaling imbalance
- Downstream signaling disruption
Metabotropic Glutamate Receptors:
- Group I mGluR (mGluR1/5) hyperactivation
- Group II/III mGluR downregulation
- Signaling pathway alterations
| Protein |
Role |
Pathology |
| PSD-95 |
Postsynaptic density scaffold |
Reduced, mislocalized |
| Homer |
mGluR anchoring |
Disrupted interactions |
| Shank |
Actin cytoskeleton link |
Loss of spines |
| SAP97 |
AMPA receptor trafficking |
Altered localization |
Aβ oligomers directly impair synaptic function:
- Binding to synaptic receptors: PrP^c, NMDA receptors, mGluR5
- 氧化应激: ROS production at synapses
- Calcium dysregulation: Channel activation, store release
- LTP impairment: Memory formation deficits
- Synaptic spine loss: Morphological changes
Pathological tau contributes to:
- Presynaptic deficits: Reduced vesicle proteins
- Postsynaptic alterations: Receptor mislocalization
- Spine loss: Direct tau toxicity to spines
- Spread: Propagation along circuits
- Reduced tyrosine hydroxylase activity
- Impaired dopamine release
- Vesicular monoamine transporter changes
- Postsynaptic receptor alterations
α-Synuclein pathology affects:
- Vesicle dynamics: Impaired vesicle cycling
- Synaptic assembly: Disruption of NSF/α-syn interactions
- Neurotransmission: Reduced release probability
- Spine morphology: Loss of dendritic spines
| Approach |
Mechanism |
Development Stage |
| Ampakines |
AMPA receptor modulators |
Phase 2 |
| NMDA partial agonists |
Targeted excitotoxicity |
Preclinical |
| BDNF mimetics |
Neurotrophic support |
Phase 1 |
| Synaptic vesicle modulators |
Enhance release |
Preclinical |
- Anti-Aβ antibodies: Reduce synaptic toxicity
- Anti-tau therapies: Prevent tau pathology spread
- α-synuclein aggregation inhibitors: Protect synapses
- Neurotrophin delivery: BDNF, NGF therapy
- Memantine: NMDA antagonist, approved for AD
- Levetiracetam: Anticonvulsant, enhances synaptic function
- Lithium: Mood stabilizer, synaptic plasticity
- Statins: Pleiotropic synaptic benefits
| Marker |
Source |
Clinical Utility |
| Neurogranin |
CSF |
Synaptic loss, AD progression |
| SNAP-25 |
CSF |
Presynaptic dysfunction |
| Synaptotagmin-1 |
CSF |
Release competence |
| PSD-95 |
Blood |
Postsynaptic integrity |
| Synaptic vesicle proteins |
CSF |
Early diagnosis |
The study of Synaptic Failure In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Selkoe DJ. (2002). Alzheimer's disease is a synaptic failure. Science. PMID:12417869
- Koffie RM, et al. (2009). Oligomeric amyloid-beta decreases the levels of membrane-associated proteins in postsynaptic densities. J Neurochem. PMID:19545271
- Shankar GM, et al. (2008). Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med. PMID:18344978
- Manczak M, et al. (2006). Mitochondria are a direct site of A beta toxicity in Alzheimer's disease neuronal synapses. J Neurosci. PMID:16436539
- Hsieh H, et al. (2006). AMPAR removal underlies Abeta-induced synaptic depression and dendritic spine loss. Neuron. PMID:16841712
- Snyder EM, et al. (2005). Regulation of NMDA receptor trafficking by amyloid-beta. Nat Neurosci. PMID:16199547
- Tai HC, et al. (2012). The synaptic accumulation of hyperphosphorylated tau oligomers in Alzheimer disease is associated with dysfunction of the ubiquitin-proteasome system. Am J Pathol. PMID:22658640
- Calabrese B, et al. (2007). Rapidtyrosine phosphorylation of kinesin in response to neuronal activity. Cell Cycle. PMID:17975544
- Zoghbi HY, et al. (2019). The-synuclein in synaptic function and dysfunction. Trends Neurosci. PMID:30686750
- Lin MT, Beal MF. (2006). Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature. PMID:17051205
- Palop JJ, Mucke L. (2010). Synaptic depression and excitatory imbalance underlie amyloid-beta-induced neuronal dysfunction. Nat Med. PMID:20974763
- Van Vickle GJ, et al. (2008). Kalirin and Trio: Src homology 3 domain adaptor proteins involved in the cytoskeletal organization of the neuronal growth cone. J Neurosci Res. PMID:18752297
- Mucke L, et al. (2000). Plaque-bearing and plaque-depleted mice. J Neurosci. PMID:11069967
- Gouras GK, et al. (2010). Intraneuronal Abeta accumulation and origin of plaque. Cold Spring Harb Perspect Med. PMID:21239584
- Forner S, et al. (2021). Synaptic Tau: A pathological or physiological phenomenon? Acta Neuropathol Commun. PMID:34579764
🔴 Low Confidence
| Dimension |
Score |
| Supporting Studies |
15 references |
| Replication |
0% |
| Effect Sizes |
25% |
| Contradicting Evidence |
0% |
| Mechanistic Completeness |
50% |
Overall Confidence: 38%